Results 21 to 30 of about 440,279 (349)

Pulmonary arteriovenous malformations with pulmonary artery hypertension: Therapeutic implication

APIK Journal of Internal Medicine, 2020
Pulmonary arteriovenous malformations (PAVMs) are rare pulmonary vascular anomalies and represent fistulous connection between arterial and venous branches without customary intervening capillary network that is vital for gas exchange. The incidence is 2–
Jayachandra, B S Meghana, Yoganand
doaj   +1 more source

Evaluation of microvasculopathy using dual-energy computed tomography in patients with chronic thromboembolic pulmonary hypertension

Pulmonary Circulation, 2021
The existence of microvasculopathy in patients with chronic thromboembolic pulmonary hypertension has been suggested. Recently, dual-energy computed tomography has been used to produce a sensitive iodine distribution map in lung fields to indicate ...
Hiroyuki Onishi, Yu Taniguchi, Yoichiro Matsuoka, Kenichi Yanaka, Yu Izawa, Yasunori Tsuboi, Shumpei Mori, Atsushi Kono, Kazuhiko Nakayama, Noriaki Emoto, Ken-ichi Hirata   +10 more
doaj   +1 more source

Hemodynamic Effects of Ketone Bodies in Patients With Pulmonary Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) are debilitating diseases with a high mortality. Despite emerging treatments, pulmonary vascular resistance frequently remains elevated.
Roni Nielsen, Kristian Hylleberg Christensen, Nigopan Gopalasingam, Kristoffer Berg‐Hansen, Jacob Seefeldt, Casper Homilius, Ebbe Boedtkjer, Mads Jønsson Andersen, Henrik Wiggers, Niels Møller, Hans Erik Bøtker, Søren Mellemkjær   +11 more
doaj   +1 more source

Pulmonary and systemic hemodynamics are associated with myocardial injury in the acute respiratory distress syndrome

Pulmonary Circulation, 2020
Background Whether right and left heart hemodynamics are associated with myocardial injury in the acute respiratory distress syndrome (ARDS) is not known.
Thomas S Metkus, Stephen C Mathai, Thorsten Leucker, Paul M Hassoun, Ryan J Tedford, Frederick K Korley   +5 more
doaj   +1 more source

Influence of advanced pulmonary vascular remodeling on accuracy of echocardiographic parameters of left ventricular filling pressure

Pulmonary Circulation, 2021
Evaluation of left ventricular filling pressure plays an important role in the clinical management of pulmonary hypertension. However, the accuracy of echocardiographic parameters for the determination of left ventricular filling pressure in the presence
Yasuyuki Chiba, Hiroyuki Iwano, Sanae Kaga, Mio Shinkawa, Michito Murayama, Hiroshi Ohira, Suguru Ishizaka, Miwa Sarashina, Shingo Tsujinaga, Shinobu Yokoyama, Masahiro Nakabachi, Hisao Nishino, Kazunori Okada, Kiwamu Kamiya, Toshiyuki Nagai, Toshihisa Anzai   +15 more
doaj   +1 more source

Transcription factors and potential therapeutic targets for pulmonary hypertension

Frontiers in Cell and Developmental Biology, 2023
Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial ...
Liu Yang, Naifu Wan, Fanpeng Gong, Xianfeng Wang, Lei Feng, Guizhu Liu   +5 more
doaj   +1 more source

Absence of reflex vascular responses from the intrapulmonary circulation in anaesthetised dogs [PDF]

, 2000
The aim of this investigation was to determine whether reflex cardiovascular responses were obtained to localised distension of the intrapulmonary arterial and venous circulations in a preparation in which the stimuli to other major reflexogenic areas ...
Drinkhill, M.J., Hainsworth, R., McMahon, N.C., Myers, D.S.   +3 more
core   +1 more source

MicroRNAs in pulmonary arterial remodeling [PDF]

, 2013
Pulmonary arterial remodeling is a presently irreversible pathologic hallmark of pulmonary arterial hypertension (PAH). This complex disease involves pathogenic dysregulation of all cell types within the small pulmonary arteries contributing to vascular ...
A Courboulin, A Eulalio, A Ishisaki, A Jelaska, A Kos, A Sacconi, A Tanzer, A Zampetaki, A Zampetaki, AE Frost, AJ Tijsen, AM Walker, Andrew H. Baker, AR Kuhn, AS Flynt, AY Rangrez, AY Yu, B Wojciak-Stothard, BD Adams, BN Davis, BN Davis-Dusenbery, C Atkinson, C Li, C Sweeney, CA Klattenhoff, CD Cool, CL Bockmeyer, D Cifuentes, D Loffler, DB Badesch, DF Liao, DM Patrick, DP Bartel, E Hergenreider, E Mathe, E Rooij Van, ED Michelakis, FE Wang, G Lagna, G Meister, G Simonneau, G Song, GK Owens, H Beppu, H Kang, H Takahashi, H Tazawa, H Valadi, HY Chiang, J Brennecke, J Kim, J Liu, J Niu, J Ryan, J Sarkar, J Skog, J-S Yang, JD Arroyo, Jennifer S. Grant, JH Newman, JM Boucher, JR Thomson, K Abe, K Rakesh, K Wang, KA O’Donnell, KB Lane, KD Taganov, Kevin White, KN Cowan, KR Cordes, KR Stenmark, KR Stenmark, L Elia, L Guo, L He, L He, L Long, L Tu, LA Brennan, LR Frumkin, M Afrakhte, M Brock, M Das, M Deo, M Humbert, M Humbert, M Humbert, M Izikki, M Rabinovitch, M Trabucchi, M Xin, Margaret R. MacLean, MC Chan, MC Chan, MD Moen, MJ Goumans, MM Hoeper, N Liu, N Raver-Shapira, N Volk, NW Morrell, O Platoshyn, P Caruso, P Fasanaro, P Sklepkiewicz, R Kulshreshtha, R Kumarswamy, R Paulin, RD Machado, RJ Dekker, RM O’Connell, S Bonnet, S Chakravarthy, S Jalali, S Mizuno, S Sakamoto, S Sakao, S Yang, SA Moschos, SS Pullamsetti, T Boettger, T Thum, TC Chang, TX Lu, U Bruning, VN Parikh, W Shi, WB Li, X Huang, X Ji, X Long, X Yang, Y Cheng, Y Cheng, Y Ling, Y Liu, YL Jiang   +137 more
core   +2 more sources

Purinergic Dysfunction in Pulmonary Arterial Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Pulmonary arterial hypertension (PAH) is a life‐threatening disease characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, which result in an increase in afterload imposed onto the right ventricle, leading to right ...
Zongye Cai, Ly Tu, Christophe Guignabert, Daphne Merkus, Zhichao Zhou   +4 more
doaj   +1 more source

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]

, 2013
BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group,, D'Armini, AM, Fritsch, A, Ghofrani, HA, Grimminger, F, Hoeper, MM, Jansa, P, Kim, NH, Mayer, E, Neuser, D, Simonneau, G, Wang, C, Weimann, G, Wilkins, MR   +13 more
core   +1 more source